Our product range

Our development pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

IgG Next Generation (BT-595) - Primary Immune Deficiency (PID)
IgG Next Generation (BT-595) - Idiopathic Thrombocytopenic Purpura (ITP)
Fibrinogen (BT-524) - Congenital fibrinogen deficiency
Fibrinogen (BT-524) - Acquired Fibrinogen Deficiency
Cytotect 70 (BT-084) - Congenital CMV infection prophylaxis
Trimodulin (BT-086) - Severe community acquired pneumonia
(BT-063) - Systemic lupus erythematosus
Indatuximab Ravtansine (BT-062) - Multiple myeloma
Indatuximab Ravtansine* (BT-062) - Solid tumors
Tregalizumab (BT-061) - other diseases

Pipeline

Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine

Further information

Press releases

Preliminary announcement of the publication of financia...

06.12.2017,

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Annual financial report Date of disclosure / German: March 22, 2018 Date of disclosure / English: March ... [More]

Preliminary announcement of the publication of quarterl...

06.12.2017,

Biotest AG hereby announces that the following financial reports shall be disclosed : Report: Quarterly financial report within the 1st half-year (Q1) Date of disclosure / German: May 15, 2018 Date ... [More]

Biotest supports a randomized multicenter controlled tr...

05.12.2017,

/PRESS RELEASEBiotest supports a randomized multicenter controlled trial in peritonitis (PEPPER trial) with Pentaglobin(R) lead by Aachen University- Trial investigates personalized treatment approach ... [More]

Biotest generates revenues of EUR 377.8 million in the ...

14.11.2017,

PRESS RELEASEBiotest generates revenues of EUR 377.8 million in the first nine months 2017- Successful regulatory inspection and approval of Biotest Next Level in August- Paul-Ehrlich Institute approv ... [More]

Tender Offer by Tiancheng (Germany) Pharmaceutical Hold...

07.11.2017,

/Ad-hoc RELEASEAnnouncement according to Article 17 European Market Abuse Regulation (MAR)Tender Offer by Tiancheng (Germany) Pharmaceutical Holdings AG / Tiancheng withdrawal of application of transa ... [More]

Biotest AG opens eighth plasma collection centre in Hun...

06.11.2017,

/PRESS RELEASEBiotest AG opens eighth plasma collection centre in Hungary- 17 plasma collection centres in Europe and- 22 in the USA to ensure long-term plasma supplyDreieich, 6 November 2017. Biotest ... [More]

Correction of a release from 24.10.2017, 10:28 CET/CEST...

26.10.2017,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisit ... [More]

Release according to Article 26, Section 1 of the WpHG ...

24.10.2017,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights X Acquisition/d ... [More]

Release according to Article 26, Section 1 of the WpHG ...

19.10.2017,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights X Acquisition/d ... [More]

Release according to Article 26, Section 1 of the WpHG ...

18.10.2017,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisit ... [More]

Correction of a release from 16.10.2017, 12:50 CET/CEST...

17.10.2017,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisit ... [More]

Release according to Article 26, Section 1 of the WpHG ...

16.10.2017,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisit ... [More]

Release according to Article 26, Section 1 of the WpHG ...

13.10.2017,

Notification of Major Holdings1. Details of issuer Biotest AG Landsteinerstraße 5 63303 Dreieich Germany 2. Reason for notification X Acquisition/disposal of shares with voting rights   Acquisit ... [More]

Biotest strengthens its position in the German haemophi...

11.10.2017,

/PRESS RELEASEBiotest strengthens its position in the German haemophilia market with the introduction of new patient support services- Biotest supports home treatment with a team of specialised nurses ... [More]

Biotest AG: Annual general meeting approves payout of d...

30.08.2017,

PRESS RELEASEBiotest AG: Annual general meeting approves payout of dividend- Dividend payout of EUR 0.05 per ordinary share and EUR 0.07 per preference shareDreieich/ Frankfurt a. M., 30 August 2017. ... [More]

Preliminary announcement of the publication of quarterl...

23.08.2017,

Biotest AG hereby announces that the following financial reports shall be disclosed for the business year 2017: Report: Quarterly financial report within the 2nd half-year (Q3) Date of disclosure / ... [More]

Biotest reported sales of EUR 247.1 million in the firs...

14.08.2017,

/PRESS RELEASEBiotest reported sales of EUR 247.1 million in the first half of 2017- Successful building inspection of the new building at Dreieich- Closing of the Public Takeover Offer is subject to ... [More]

Biotest takes over Cara Plasma s.r.o. with one plasma c...

19.07.2017,

PRESS RELEASEBiotest takes over Cara Plasma s.r.o. with one plasma collection centre in the Czech Republic- Long-term plasma supplier Cara Plasma was taken over by Biotest- Biotest has now 16 plasma c ... [More]

Biotest reaches 2nd milestone in Biotest Next Level exp...

22.06.2017,

Biotest reaches 2nd milestone in Biotest Next Level expansion project- Authorities grant building approval- Relocation activities of laboratories and offices for production start in June Dreieich ... [More]

Biotest AG shareholders accept voluntary public tender ...

14.06.2017,

PRESS RELEASEBiotest AG shareholders accept voluntary public tender offer by CREAT GroupDreieich, 14 June, 2017. The shareholders of Biotest AG have accepted the voluntary public tender offer by Tianc ... [More]

Careers

Careers

Passionate to help us save lives?

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.

Letter to shareholders

preview

Letter to shareholders - 4.11.2015
PDF, 162 KB
[ Download ]